Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.

ABSTRACT:

Aims

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiovascular and renal benefits in type 2 diabetes, but their real-world effects in individuals with obesity without diabetes are unclear. This study aimed to evaluate the cardiovascular and kidney outcomes of GLP-1RAs versus other anti-obesity medications (AOMs) in adults with obesity.

Materials and methods

This target trial emulation used TriNetX electronic health records (July 2021-May 2025) to identify adults with obesity and no diabetes history who initiated GLP-1RAs (liraglutide, semaglutide, or tirzepatide) or other AOMs. Outcomes included major adverse cardiovascular events (MACE), major adverse kidney events (MAKE), all-cause mortality, mental health conditions, and safety outcomes. Propensity score

SUBMITTER: Tang H 

PROVIDER: S-EPMC12515787 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature